FDA orders withdrawal of Palatin radiology drug pending adverse advents review
This article was originally published in Clinica
Executive Summary
Palatin Technologies has recalled an imaging agent at the behest of the FDA after two people died and 20 others experienced life-threatening complications when the product was used on an off-label basis.